Figure 1.

Images of lesions in two patients treated with avelumab in the expanded access program. Patient 1: patient with large, ulcerated, intransit lesions at baseline (A), which regressed after two avelumab infusions (B); the patient subsequently received a skin graft (C). Patient 2: baseline (D and F) and post-treatment (E and G) FDG-PET CT images of a patient with chemotherapy-refractory metastatic Merkel cell carcinoma who achieved a complete response following four cycles of avelumab. Images A–C were kindly provided by JWW, while images D–G were kindly provided by RM. FDG, fluorodeoxyglucose; PET, positron emission tomography.